Prices are updated after-hours

Health Technology Education

CymaBay Therapeutics Inc.

CBAY | $32.48 0.03% 8.4M

(0.0% 1d) (0.0% 1m) (229.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-56.22% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 3,726,247,895
http://www.cymabay.com
Sec Filling | Patents | 60 employees

(US) CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

education liver liver disease

add to watch list Paper trade email alert is off

Neovasc Inc.

NVCN | $30.03 1.66% -2.02% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (615.5% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 81,306,886
http://www.neovasc.com
Sec Filling | Patents | 110 employees

(CA) Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. Its focuses on Neovast Tiara, and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

education cosira-ii heart

add to watch list Paper trade email alert is off

Reata Pharmaceuticals, Inc.

RETA | $172.36 0.02% 0.03% 0

Health Technology

(0.0% 1d) (0.0% 1m) (72.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (165.53% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 5,789,158,047
http://www.reatapharma.com
Sec Filling | Patents | 220 employees

(US) Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

education

add to watch list Paper trade email alert is off

Citius Pharmaceuticals, Inc.

CTXR | $0.7199 -6.18% -6.58% 880K

Health Technology

(0.0% 1d) (-4.0% 1m) (-46.2% 1y) (0.0% 2d) (5.5% 3d) (2.7% 7d) (-48.58% volume)
Earnings Calendar: 2023-12-21
Market Cap: $ 114,532,333
http://www.citiuspharma.com
Sec Filling | Patents | 9 employees

(US) Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. It is currently advancing three proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; CITI-002, which provides anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and CITI-101, which is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

cancer education antibiotics aesthetic hemorrhoids bloodstream ontak injection

add to watch list Paper trade email alert is off

Ensysce Biosciences Inc

ENSC | $0.5583 1.58% 43K

Health Technology

(0.0% 1d) (-29.9% 1m) (-84.7% 1y) (0.0% 2d) (3.7% 3d) (-1.8% 7d) (-18.24% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 4,091,877
https://ensysce.com
Sec Filling | Patents | 4 employees

Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.

education

add to watch list Paper trade email alert is off

Avanos Medical, Inc.

AVNS | $18.71 -0.27% 0.0% 170K

Health Technology

(0.0% 1d) (-3.8% 1m) (-38.0% 1y) (0.0% 2d) (-1.0% 3d) (0.3% 7d) (-32.31% volume)
Earnings Calendar:
Market Cap: $ 864,457,980
http://www.avanos.com
Sec Filling | Patents | 4700 employees

(US) Avanos Medical, Inc. is a medical technology company, which focuses on delivering clinically medical device solutions to improve patients' quality of life. Its portfolio of innovative product offerings focused on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

education respiratory brands

add to watch list Paper trade email alert is off

AxoGen, Inc.

AXGN | $6.875 -1.36% -1.38% 120K

Health Technology

(0.0% 1d) (-6.1% 1m) (-24.6% 1y) (0.0% 2d) (1.6% 3d) (7.2% 7d) (-59.25% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 300,353,137
http://www.axogeninc.com
Sec Filling | Patents | 394 employees

AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

education treatment

add to watch list Paper trade email alert is off

Galera Therapeutics, Inc.

GRTX | $0.1821 -6.13% -6.53% 810K

Health Technology

(0.0% 1d) (-15.2% 1m) (-93.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-47.39% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 9,904,814
http://www.galeratx.com
Sec Filling | Patents | 32 employees

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm involves in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

cancer education radiation therapy oral mucositis fibrosis msa treatment

add to watch list Paper trade email alert is off

Radius Health, Inc.

RDUS | $17.9 1.47% 1.45% 320K

Health Technology

(0.0% 1d) (-7.5% 1m) (-40.2% 1y) (0.0% 2d) (-2.9% 3d) (-5.7% 7d) (29.02% volume)
Earnings Calendar: 2024-01-04
Market Cap: $ 497,300,682
http://www.radiuspharm.com
Sec Filling | Patents | 383 employees

(US) Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.

breast cancer cancer education endocrine hormone urea women osteoporosis elacestrant

Drugs

Tymlos (abaloparatide)

add to watch list Paper trade email alert is off

Axonics Modulation Technologies, Inc.

AXNX | $66.67 0.3% 0.3% 400K

Health Technology

(0.0% 1d) (-3.3% 1m) (14.3% 1y) (0.0% 2d) (-0.6% 3d) (-0.7% 7d) (NaN% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 3,400,398,611
http://www.axonicsmodulation.com
Sec Filling | Patents | 302 employees

(US) Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.

education msa treatment communication eletrical

add to watch list Paper trade email alert is off

PainReform Ltd.

PRFX | $0.841 -5.48% -5.8% 23K

Health Technology

(0.0% 1d) (-50.6% 1m) (-83.8% 1y) (0.0% 2d) (4.7% 3d) (2.2% 7d) (22.1% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 1,704,070
http://www.painreform.com
Sec Filling | Patents | n/a employees

PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

education opioid israel msa

add to watch list Paper trade email alert is off

Neuronetics, Inc.

STIM | $3.76 -2.59% -2.66% 21K

Health Technology

(0.0% 1d) (-18.0% 1m) (73.1% 1y) (0.0% 2d) (3.2% 3d) (0.8% 7d) (-24.56% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 112,704,560
http://www.neuronetics.com
Sec Filling | Patents | 235 employees

(US) Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

education treatment

add to watch list Paper trade email alert is off

Virios Therapeutics Inc

VIRI | $0.436 1.16% 1.15% 200K

Health Technology

(0.0% 1d) (-8.5% 1m) (-55.7% 1y) (0.0% 2d) (0.0% 3d) (-2.3% 7d) (9.52% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 8,396,461
https://www.virios.com
Sec Filling | Patents | 3 employees

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ('FM'). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ('HSV-1') has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease ('IBS'), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate ('IMC-1'), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

fibromyalgia education antiviral rsv

add to watch list Paper trade email alert is off

4D Molecular Therapeutics Inc

FDMT M | $24.255 -2.24% -2.29% 290K

Health Technology

(0.0% 1d) (-26.2% 1m) (18.0% 1y) (0.0% 2d) (-6.0% 3d) (-0.7% 7d) (16.69% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 1,240,824,483
https://www.4dmoleculartherapeutics.com
Sec Filling | Patents | 83 employees

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

urea ceiling education antibody gene therapies t-cell

add to watch list Paper trade email alert is off

Retractable Technologies, Inc.

RVP P | $1.08 0.94% 0.93% 25K

Health Technology

(0.0% 1d) (-11.5% 1m) (-38.2% 1y) (0.0% 2d) (0.0% 3d) (0.9% 7d) (-26.19% volume)
Earnings Calendar:
Market Cap: $ 32,332,132
http://www.retractable.com
Sec Filling | Patents | 140 employees

Retractable Technologies, Inc. manufactures and markets safety needle devices for the healthcare industry. Its products are designed to protect healthcare workers, patients, and others from needlestick injuries, cross-contamination through reuse, and reduce disposal costs. Its products include VanishPoint and Patient Safe Syringes, EasyPoint Needles, VanishPoint Blood Collection Sets and Tube Holders, VanishPoint IV Catheters. The company was founded by Thomas J. Shaw on May 9, 1994 and is headquartered in Little Elm, TX.

education

add to watch list Paper trade email alert is off

Lexaria Bioscience Corp

LEXX | $2.18 -2.68% -2.75% 98K

Health Technology

(0.0% 1d) (-43.3% 1m) (1.8% 1y) (0.0% 2d) (-1.3% 3d) (1.8% 7d) (56.67% volume)
Earnings Calendar:
Market Cap: $ 28,090,767
https://www.lexariaenergy.com
Sec Filling | Patents | 3 employees

Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide.

housing bloodstream education antiviral food

add to watch list Paper trade email alert is off

Helius Medical Technologies, Inc.

HSDT | $4.82 -3.21% -3.32% 17K

Health Technology

(0.0% 1d) (-12.5% 1m) (-47.4% 1y) (0.0% 2d) (-2.0% 3d) (-3.1% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 4,276,762
http://www.heliusmedical.com
Sec Filling | Patents | 19 employees

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

education neurological

add to watch list Paper trade email alert is off

TELA Bio, Inc.

TELA | $4.47 0.0% 85K

Health Technology

(0.0% 1d) (-17.8% 1m) (-52.4% 1y) (0.0% 2d) (-2.2% 3d) (-5.9% 7d) (-22.86% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 110,203,107
http://www.telabio.com
Sec Filling | Patents | 89 employees

TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.

education

add to watch list Paper trade email alert is off

Viatris Inc.

VTRS | News A | $11.55 1.67% 1.65% 7.2M

Health Technology

(0.0% 1d) (-4.0% 1m) (23.7% 1y) (0.0% 2d) (1.0% 3d) (2.2% 7d) (-8.32% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 13,856,200,050
http://www.viatris.com
Sec Filling | Patents | 35000 employees

Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

education diagnostics dividends!

add to watch list Paper trade email alert is off

Vivos Therapeutics Inc

VVOS | $2.58 -2.64% -2.71% 75K

Health Technology

(0.0% 1d) (-41.8% 1m) (648.8% 1y) (0.0% 2d) (0.4% 3d) (-2.6% 7d) (14.89% volume)
Earnings Calendar: 2022-11-28
Market Cap: $ 7,694,257
https://www.vivoslife.com
Sec Filling | Patents | 115 employees

Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Combining technologies and protocols that alter the size, shape and position of the tissues of the upper human airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. Sales of the Vivos System are driven by the Vivos Integrated Practice (VIP) program, which offers dentists training and value-added services in connection with their use of the Vivos System.

treatment education

add to watch list Paper trade email alert is off